Growth is driven by the rising prevalence of diabetes among the elderly, necessitating efficient insulin delivery solutions ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for diabetes and obesity.

Drucker and three co-winners made discoveries about glucagon-like peptide-1 in their labs. The other recipient of the award, ...

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures,” said Kevin McCulloch, President and COO of Xeris. “American Regent is the ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to ...

MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...

Supervised lifestyle intervention from a medical professional may help maximize fat loss and minimize muscle tissue loss in people taking the potent weight loss drugs.